The increased expression of immunosuppressive cells seen in p53-mutant AML when combined with these findings suggests that both relapsed AML and p53-mutant AML exhibit an immunosuppressive microenvironment which can be exploited with immunotherapy. The gene discussed is TP53; the disease is acute myeloid leukemia.